RxDoctor Payments Data

Philip Lepkowski, MD

Family Medicine · Toledo, OHNPI 1073513198

Payments from drug & device makers

$26,152in general payments, 2019–2025

Across 1,246 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novo Nordisk$3K
  • Amgen$3K
  • Bayer$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • plus $11K from 45 others

What the payments were for

  • Food & beverage$25,94099%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,152 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$212,917
Medicare patients
178
Services billed
7,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin266$333,173
FarxigaDapagliflozin Propanediol286$263,807
OzempicSemaglutide113$181,531
EliquisApixaban89$82,506
TrulicityDulaglutide39$68,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$52,614
VraylarCariprazine Hcl12$47,965
KerendiaFinerenone26$42,630
EntrestoSacubitril/Valsartan29$37,784
XareltoRivaroxaban24$35,546
RybelsusSemaglutide24$33,888
TrintellixVortioxetine Hydrobromide25$28,079
Victoza 3-PakLiraglutide15$22,692
MounjaroTirzepatide14$22,261
MyrbetriqMirabegron21$21,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$1,092$338,869277 claims
AstraZenecaFarxiga$3,675$263,807286 claims
Novo NordiskOzempic, Rybelsus$3,324$215,419137 claims
Lilly USA, LLCTrulicity, Mounjaro$1,462$90,70453 claims
PfizerEliquis$1,143$82,50689 claims
AbbVieVraylar, Restasis$1,682$55,10732 claims
GSKTrelegy Ellipta$286$52,61444 claims
Johnson & JohnsonXarelto, Invokana$668$44,00441 claims
BayerKerendia$1,977$42,63026 claims
NovartisEntresto$706$37,78429 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$240$28,07925 claims
Astellas Pharma US IncMyrbetriq$177$21,20521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →